Smoking cessation strategies in patients with lung disease

In Vivo

Volumn 27, Issue 2, 2013, Pages 171-176

  Georgia, Tsiapa ^a   Gkiozos, Ioannis ^a   Souliotis, Kyriakos ^a   Syrigos, Kostas ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Bupropion; Lung cancer; Nicotine replacement therapy; Pulmonary disease; Review; Smoking cessation; Varenicline

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE PATCH; NORTRIPTYLINE; PLACEBO; VARENICLINE; BENZAZEPINE DERIVATIVE; NICOTINE GUM; NICOTINIC RECEPTOR BLOCKING AGENT; QUINOXALINE DERIVATIVE;

ARTICLE; BEHAVIOR THERAPY; BLURRED VISION; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; FOLLOW UP; HUMAN; LUNG DISEASE; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; SEDATION; SIDE EFFECT; SMOKING CESSATION; TOBACCO DEPENDENCE; URINE RETENTION; XEROSTOMIA; CLINICAL TRIAL (TOPIC); DIRECTIVE COUNSELING; MEDLINE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; REVIEW; TREATMENT OUTCOME;

BENZAZEPINES; BUPROPION; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DIRECTIVE COUNSELING; HUMANS; LUNG DISEASES; NICOTINIC ANTAGONISTS; PUBMED; QUINOXALINES; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TREATMENT OUTCOME;

EID: 84876905735     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Fiore MC, Jaén CR, Baker TB and Bailey W: Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service. 2008.
2. Ebbert JO, Sood A, Hays JT, Dale LC and Hurt RD: Treating tobacco dependence: Review of the best and latest treatment options. J Thorac Oncol 2: 249-256, 2007.
3. US Department of Health and Human Services. Clinical Practice Guideline: Treating Tobacco Use and Dependence A report from the Surgeon General. US Department of Health and Human Services, Public Health Services, Office of the Surgeon General, 2000.
4. Sutherland G, Stapleton JA, Russel MAH, Jarvis MJ, Hajek P, Belcher M and Feyerabend C: Randomized controlled trial of nasal nicotine spray in smoking cessation. Lancet 340: 324-329, 1992.
5. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M and Doan K: Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. Addiction 91: 1293- 1306, 1996.
6. Fiore MC, Smith SS, Jorenby DE and Baker TB: the effectiveness of the nicotine patch for smoking cessation. JAMA 271: 1940-1947, 1994.
7. Herrera N, Franco R, Herrera L, Partidas A, Rolando R and Fagerstrom KO: Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. Chest 108(2): 447-451, 1995.
8. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA and Lerman C: Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 152: 144-151, 2010.
9. Tønnesen P, Nørregaard J, Mikkelsen K, Jørgensen S and Nilsson F: A double-blind trial of nicotine inhaler for smoking cessation. JAMA 269: 1268-1271, 1993.
10. Tang JL, Law M, Wald N: How effective is nicotine replacement therapy in helping people to stop smoking. BMJ 308(6920): 21-26, 1994.
11. Silagy C, Lancaster T, Stead L, Mant D and Fowler G: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 3:CD000146, 2004.
12. Tønnesen P, Mikkelsen K and Bremann L: Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 130(2): 334-342, 2006.
13. Tønnesen P, and Mikkelsen K. Smoking cessation with four nicotine regiments in a lung clinic. Eur Respir J 16: 717-722, 2000.
14. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE and O'Hara P: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The lung health study. JAMA 272: 1497-1505, 1994.
15. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC and Buist AS: Smoking cessation and lung function in mild-tomoderate chronic obstructive pulmonary disease. the Lung Health Study. Am J Respir Crit Care Med 161: 381-390, 2000.
16. Rennard SI and Daughton DM: Smoking cessation. Chest 117: 360-364, 2000.
17. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC and Baker TB: A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685-691, 1999.
18. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT and Sullivan PM: A comparison of sustained-release bupropion for smoking cessation. N Engl J Med 337: 1195-1202, 1997.
19. Haggsträm FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF and Fritscher CC: A Controlled Trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. Pulmonary Pharmacology and Therapeutics 19: 205-209, 2006.
20. Hall SM, Humfleet GL, Reus VI, Muñoz RF, Hartz DT and Maude-Griffin R: Psychological Intervention and Antidepressant Treatment in Smoking Cessation. Arch Gen Psychiatry 59(10): 930-936, 2002.
21. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK and Jamerson B: Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet 357: 1571-1575, 2001.
22. Wagena EJ, Knipschild PG, Huibers MJH, Wouters EFM and van Schayck CP. Efficacy of Bupropion and Nortriptyline for Smoking Cessation Among People at Risk for or With Chronic Obstructive Pulmonary Disease. Arch Intern Med 165: 2286- 2292, 2005.
23. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE and Reeves KR: Varenicline Phase 3 Study Group: Varenicline, an a4b2 nicotinic acetycholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296: 47-55, 2006.
24. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J and Reeves KR; Varenicline Phase 3 Study Group: Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: A randomized controlled trial. JAMA 296: 56-63, 2006.
25. Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB and Reeves KR: Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 296: 64-71, 2006.
26. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R and Reeves K: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 166: 1571- 1577, 2006.
27. Park ER, Japuntich S, Temel J, Lanuti M, Pandiscio J, Hilgenberg J, Davies D, Dresler C and Rigotti NA: A smoking cessation intervention for thoracic surgery and oncology clinics: A pilot trial. J Thorac Oncol 6(6): 1059-1065, 2011.
28. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D and Lee TC: Effects of varenicline on smoking cessation in patients with mild to moderate COPD: A randomized controlled trial. Chest 139(3): 591-599, 2011.
29. Gourlay SG, Stead LF and Benowitz NL: Clonidine for smoking cessation. Cochrane Database Syst Rev CD000058(3), 2004.
30. da Costa CL, Younes RN and Lourenço MT. A prospective, randomized, double-blind study comparing nortriptyline to placebo. Chest 122(2): 403-408, 2002.
31. Hall SM, Reus VI, Muñoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S and Triffleman E: Nortriptyline and cognitivebehavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55: 683-690, 1998.
32. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA and Lofaso D: A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 158: 2035-2039, 1998.
33. Hall SM, Humfleet GL, Reus VI, Muñoz RF, Hartz DT and Maude-Griffin R: Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 59: 930- 936, 2002.
34. Kotz D, Wesseling GJ, Huibers MJH and van Schayck CP: Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 33: 754-762, 2009.
35. Mottillo S, Filion KB, Bélisle P, Joseph L, Gervais A, O'Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, Tremblay M and Eisenberg MJ: Behavioural interventions for smoking cessation: A meta-analysis of randomized controlled trials. Eur Heart J 30: 718-730, 2009.
36. Tønnesen P, Mikkelsen K, Markholst C, Ibsen A, Bendixen M, Pedersen L, Fuursted R, Hansen LH, Stensgaard H, Schiøtz R, Petersen T, Breman L, Clementsen P and Evald T: Nurseconducted smoking cessation with minimal intervention in a lung clinic: A randomized controlled study. Eur Respir J 9(11): 2351-2355, 1996.
37. Research Committee of the British Thoracic Society: Smoking cessation in patients: two further studies by the British Thoracic Society. Thorax 45: 835-840, 1990.
38. Garces YI, Yang P, Parkinson J, Zhao X, Wampfler JA, Ebbert JO and Sloan JA: the relationship between cigarette smoking and quality of life after lung cancer diagnosis. Chest 126: 1733- 1741, 2004.
39. Videtic GM, Stitt LW, Dar AR, Kocha WI, Tomiak AT, Truong PT, Vincent MD and Yu EW: Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limitedstage small-cell lung cancer is associated with decreased survival. J Clin Oncol 21: 1544-1549, 2003.
40. Tammemagi CM, Neslund-Dudas C, Simoff M and Kvale P: Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 125: 27-37, 2004.
41. Rubins J, Unger M and Colice GL: Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest 132(3): 355-367, 2007.
42. Chandler MA and Rennard SI: Smoking cessation. Chest 137: 428-435, 2010.